Rotigotine
- Generic Name
- Rotigotine
- Brand Names
- Neupro
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25NOS
- CAS Number
- 99755-59-6
- Unique Ingredient Identifier
- 87T4T8BO2E
- Background
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
...
- Indication
For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 68
- Registration Number
- NCT01744496
- Locations
- 🇺🇸
2101, Roanoke, Virginia, United States
🇺🇸2104, Milwaukee, Wisconsin, United States
🇵🇱1607, Gdansk, Poland
A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 90
- Registration Number
- NCT01723904
- Locations
- 🇦🇺
402, Chatswood, New South Wales, Australia
🇰🇷112, Busan, Korea, Republic of
🇰🇷101, Seoul, Korea, Republic of
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 87
- Registration Number
- NCT01711866
- Locations
- 🇰🇷
106, Seoul, Korea, Republic of
🇰🇷102, Busan, Korea, Republic of
🇺🇸505, Anniston, Alabama, United States
Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 346
- Registration Number
- NCT01646255
- Locations
- 🇨🇳
Sp1037 006, Wuhan, China
🇨🇳Sp1037 001, Beijing, China
🇨🇳Sp1037 002, Beijing, China
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2015-08-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 249
- Registration Number
- NCT01646268
- Locations
- 🇨🇳
025, Beijing, China
🇨🇳016, Tianjin, China
🇨🇳021, Fuzhou, China
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 150
- Registration Number
- NCT01569464
- Locations
- 🇺🇸
012, Macon, Georgia, United States
🇺🇸015, St. Louis, Missouri, United States
🇺🇸019, Kalamazoo, Michigan, United States
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- UCB BIOSCIENCES GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT01537042
- Locations
- 🇺🇸
603, West Seneca, New York, United States
🇺🇸601, Austin, Texas, United States
🇫🇮201, Helsinki, Finland
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01536015
- Locations
- 🇺🇸
014, Houston, Texas, United States
🇺🇸032, Annapolis, Maryland, United States
🇺🇸016, Commack, New York, United States
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- UCB Korea Co., Ltd.
- Target Recruit Count
- 380
- Registration Number
- NCT01523301
- Locations
- 🇰🇷
08, Busan, Korea, Republic of
🇰🇷03, Ansan, Korea, Republic of
🇰🇷26, Busan, Korea, Republic of
Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01498120
- Locations
- 🇺🇸
012, Los Angeles, California, United States
🇺🇸001, Destrehan, Louisiana, United States
🇺🇸013, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.